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ABSTRACT  
In the current scenario of pharmaceutical research much attention has been focused on patients health in terms of therapeutic efficacy and 
economical standards (price factor).The formulation design consist of core tablets designed by direct compression method. Core tablets were 
coated with a naturally occurring swelling agent (carbopol & Karaya gum). Evaluation studies were performed for prepared pulsatile tablets 
hardness. In in vitro release profile of 6 hours study in first 5 hours it shows minimum drug release and at the end of six hours rapid and 
transient release was observed. Stability studies proved that coating of tablets seems to decrease the effect of temperature and moisture on 
degradation of Zafirlukast. The pulsatile release has been achieved from tablet over a 7-8 hour period.   
Objectives: 
1. To Prepare and evaluate the pulsatile drug delivery system of zafirlukast. 
2. To perform in-vitro drug release studies and to assess drug release studies. 
Methodology: Methodology of the present research include the preparation of core tablet by Direct compression method. Preparation of 
coated tablet by preparing 16mm die, placing the core tablet manually at center and compression was done in rotary compressio n tablet 
machine using16.4x8mm flat oval shape punch.  
Results: Pre-compression parameters were conducted for all formulations blend and were found to be satisfactory. Bulk density was found in 
the range 0.340 - 0.384 g/sq cm and tapped density in the range of 0.394 - 0.434 g/sq cm. Using these two density factors Hausner’s ratio and 
compressibility index was calculated. The powder blend of all formulations had Hausner’s ratio was between 1.11 – 1.17 which indicates better 
flow property and compressibility index between 10.74 to 14.88 which indicates fair flow ability property. The fair flow abil ity property of the 
powder blend was also evidenced with angle of repose between 25.24–27.97 which is below 40 indicating good flow ability.  
Conclusion: A satisfactory attempt was made towards the development of efficacious drug delivery systems with already existing  active 
ingredient (Zafirlukast). The coating given by the combination of carbopol and Karayagum enhanced the drug release from the c oated tablet 
and side effects were minimized. 
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INTRODUCTION:  
In the current scenario of pharmaceutical research much 
attention has been focused on patient’s health in terms of 
therapeutic efficacy and economical standards (price 
factor).The major goal for the drug delivery research is 
turned towards the development of efficacious drug delivery 
systems with already existing active ingredients. 
Pulsatile drug delivery system: Pulsatile drug delivery 
system is most interesting and time specific system as per 
pathophysiological need of the disease.  Pulsatile drug 
delivery system is characterized by time period of no release 
(lag time) followed by a rapid and complete drug release. 
The drug release was influenced by type of pulsatile delivery 
mechanism employed in the formulation (Capsular system, 
Osmotic system, rupturable polymeric coating). The lag time 
was reduced by replacing the swelling agents and 
disintegrating agents.  By reducing the lag time the drug 
release was done before the actual time of release1. 
Swelling agent2: Swelling agent is used in the designing of 
dosage form to reduce the frequency of dosing by modifying 
the rate of drug release kinetics as well as dry absorption.  It 
Madhavi et al                                                                                                        Journal of Drug Delivery & Therapeutics. 2020; 10(2):122-128 
ISSN: 2250-1177                                                                                  [123]                                                                                 CODEN (USA): JDDTAO 
was proven that naturally occurring polymers are more 
efficient compared to chemical and synthetic in terms of 
patient health. The natural swelling agent employed in the 
formulation is Karaya gum. 
The swelling behavior of karaya gum depends upon the 
presence of acetyl groups in its structure. Karaya gum swells 
in 60% alcohol, but remains insoluble in other organic 
solvents karaya may absorb up to 100 times its weight in 
water5. The major use of karaya gum is as a bulk laxative in 
view of its ability to form a mucilaginous gel on contact with 
water.   
Swelling index: The extent of swelling was measured in 
terms of % weight gain by the granules. The swelling 
behavior of all formulations was studied. 2 gram from each 
formulation was kept in a Petri dish containing pH 6.8 
phosphate buffers. At the end of 1 hour, the Petri dish along 
with the granules was weighed. The weight of the granules, 
were noted, and the process was continued till the end of 24 
hours. The swollen granules were weighed (W2) and the 
percentage of swelling was calculated by the following 
equation6. 
Swelling index= (W2-W1)\W1*100 
W2=weight after absorption 
W1= weight before absorption  
MATERIALS AND METHODS: 
Materials: Zafirlukast, Polyplasdone XL 10, Ac-Di-Sol, 
Primojel, Micro crystalline cellulose, Talc, Magnesium 
stearate, Carbopol, Karaya gum. Other excipients are 
procured from Narmada chemicals. 
Formulation of Compressed Tablets of Zafirlukast 
The methodology adopted includes: 
 Preparation of core tablet of Zafirlukast. 
 Coating of the core tablets 
1. Formulation of core tablet of Zafirlukast: The inner 
core tablets were prepared by using direct 
compression method as per the developed formulation 
table Accurately weighed amounts of Zafirlukast, MCC, 
Polyplasdone XL 10, Ac-Di-Sol, Primojel, and Talc were 
dry blended for about 15min followed by addition of 
magnesium stearate. The mixture was then further 
blended for 10 min. Now the resultant powder blend 
was manually compressed using punching machine 
and finally the core tablet was obtained. 
2. Formulation of coated tablets of Zafirlukast: The 
optimized core tablets were coated with coating 
ingredients like Carbopol, Karaya gum.  Now 
accurately weighed amount of barrier layer material 
was transferred into a 16mm die then the core tablet 
was placed manually at the center. The remaining 
amount of the barrier layer material was added into 
the die and compressed. Compression of tablets was 
done in rotary compression tablet machine 
using16.4x8mm flat oval shape punch. The prepared 
tablet of each batch was evaluated for the tablet 
properties. 
Evaluation of Formulations: 
1. Compatibility Studies: Compatibility with excipients 
was confirmed by FTIR studies. The pure drug and 
polymers were subjected to FTIR studies. In the 
present study, the potassium bromide disc (pellet) 
method was employed. 
2. Preparation of Standard Calibration Curve of 
Zafirlukast in 0.1 N HCL: 100mg of zafirlukast was 
accurately weighed and transferred into100ml 
volumetric flask. It was dissolved and diluted to volume 
with 0.1 N HCL buffer to give stock solution containing 
1000µg/ml. The standard stock solution was then 
serially diluted with 0.1N HCL buffer to get 2to10µg/ml 
of zafirlukast. The absorbance of the solution was 
measured against 0.1 N HCL buffer as blank at 230 nm 
using UV visible spectrophotometer. The absorbance 
values were plotted against concentration (µg/ml) to 
obtain the standard calibration curve. 
Evaluation of Pre-Formulation Parameters: 
1. Angle of repose: The angle of repose of powder blend 
was determined by the funnel method. The accurately 
weight powder blend were taken in the funnel. The 
height of the funnel was adjusted in such away the tip 
of the funnel just touched the apex of the powder blend. 
The powder blend was allowed to flow through the 
funnel freely onto the surface. The diameter of the 
powder cone was measured and angle of repose was 
calculated by using fallowing equation. 
Tan θ = h/r  
Where, h and r are the height and radius of the powder cone 
respectively. 
2. Determination of Bulk Density and Tapped Density: 
20g of the granules (W) from each formula were 
introduced into a 100mlmeasuring cylinder, and the 
initial volume was observed. The cylinder was allowed 
to fall under its own weight onto a hard surface from 
the height of 2.5cm at 2Sec intervals. The tapping was 
continued until no further change in volume was noted. 
The bulk density, and tapped density were calculated 
using the following formulae. 
Bulk density=W/ VO 
Tapped density=W/ VF 
Where, W=weight of the granules,  
VO =initial volume of the granules,  
VF =Zafirlukast volume of the granules. 
3.  Hausner’s Ratio 
4. Compressibility index (Carr’s Index) 
Evaluation of tablet properties: 
1. Weight variation: The weight of the tablet being made 
was routinely determined to ensure that tablet contains 
the proper amount of drug. The USP weight variation 
test is done by weighing 20tablets individually, 
calculating the average weight and comparing the 
individual weights to the average. The tablets met the 
USP specification that not more than 2 tablets are 
outside the percentage limits and no tablet differs by 
more than 2times the percentage limit. 
2. Tablet hardness: The resistance of tablets to shipping 
or breakage under conditions of storage, transportation 
and handling before usage depends on its hardness. 
The hardness of each batch of tablet was checked by 
using Monsanto hardness tester. The hardness was 
measured in terms of kg/cm2. 3 tablets were chosen 
randomly and tested for hardness. The average 
hardness of 3 determinations was recorded. 
3. Friability:  20 tablets were weighed and the initial 
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weight of these tablets was recorded and placed in 
Roche friabilator and rotated at the speed of 25rpm for 
100 revolutions. Then tablets were removed from the 
friabilator, dusted off the fines and again weighed and 
the weight was recorded. 
4. Tablet thickness: Thickness of the tablet is important 
for uniformity of tablet size. Thickness was measured 
using vernier Callipers. It was determined by checking 
the thickness often tablets of each formulation. 
5. Content Uniformity: The tablets were tested for their 
drug content uniformity .At random 20tablets were 
weighed and powdered. The powder equivalent to 
200mg was weighed accurately and dissolved in 100ml 
of buffer used. The solution was shaken thoroughly. 
The un dissolved matter was removed by filtration 
through Whattman’s filter paper No.41. Then the serial 
dilutions were carried out. The absorbance of the 
diluted solutions was measured at 230 nm. The 
concentration of the drug was computed from the 
standard curve of the Zafirlukast in 6.8 phosphate 
buffer. 
6. Disintegration time: Tablet disintegration is an 
important step in drug absorption. The test for 
disintegration was carried out in Electro lab USP 
disintegration test apparatus. It consists of 6glasstubes 
which are 3inches long, open at the top, and held 
against a1 0mesh screen, at the bottom end of the 
basket rack assembly. To test the disintegration time of 
tablets, one tablet was placed in each tube and the 
basket rack was position Edina 1 litre beaker 
containing 6.8 phosphate buffer solution at 37°C±1°C 
such that the tablet remains 2.5cm below the surface of 
the liquid. The time taken for the completed is 
integration of the tablets was noted. 
7. In vitro Dissolution time: In-vitro dissolution study of 
core and coated tablets of Zafirlukast was carried out 
using Electro lab TDT-08L USP dissolution test 
apparatus. The details are given as below: 
Procedure: Tablet was introduced into the basket of the 
Electrolab TDT-08L USP dissolution test apparatus and the 
apparatus was set in motion, 5ml of sample was withdrawn 
for half a n  hour at 5min intervals. Samples withdrawn 
were analyzed by UV-spectrophotometer for presence of 
drug using buffer solution as blank.  
Evaluation of Pulsatile Drug Delivery Systems: 
1. Characteristics of coated tablets of Zafirlukast: 
Characteristics of tablets of Zafirlukast such as 
hardness and disintegration test were conducted.  
3tablets were taken and hardness off or formulations 
was determined by using Monsanto hardness tester. 
Average of three determinations was noted down. 6 
tablets were taken in Electrolab USP Disintegration test 
apparatus and disintegration time of tablets was 
determined using pH 6.8 buffer. Thickness of coated 
Zafirlukast tablet formulations was determined by 
using digital Vernier calipers. 3 tablets of each type of 
coated formulation were determined for thickness and 
average thickness of the formulation was determined. 
Similarly the thickness of the coating on the 
formulation was determined by deducting the 
thickness of core tablets from thickness of the coated 
formulation. A successful Pulsatile drug delivery 
system is one that remains intact in the physiological 
environment of stomach and small intestine for upto 
six hours, releasing no or minimum  amount of drug, 
but completely releases the drug after six hours. 
2. In-vitro Dissolution methods: Dissolution testing of 
pulsatile delivery systems with the conventional 
paddle method at 50rpm and 37±0.5°Ch as usually 
been conducted in different buffers for different 
periods of time to simulate the GI tract pH and transit 
time that the pulsatile delivery system might encounter 
in-vivo .The ability of the coats/carrier store main 
intact in the physiological environment of the stomach 
and small intestine is generally assessed by conducting 
drug release studies in 0.1N HCL for 2hours (mean 
gastric emptying time) and in pH6. 8phosphate buffer 
for remaining hours (mean small intestinal transit 
time) using USP dissolution rate test apparatus. The 
samples were withdrawn at regular intervals and 
analyzed by UV spectrophometer (Shimadzu UV/Vis 
1800) for the presence of the drug. Dissolution tests 
were performed in triplicate. Despite the simplicity and 
convenience, convention al dissolution testing 
primarily provides essential information on the 
processing specifications of a pulsatile drug delivery 
system rather than on the validity of the system design. 
3. Stability Studies: In the present study optimized 
formulation was selected for the study and 
formulations were packed in amber-colored bottles 
tightly plugged with cotton and capped. 
They were exposed to 40
o
C temp and 75%RH for 30days.At 
regular intervals, the tablets were taken in 100ml of pH 
6.8buffer and were shaken for 1hr.The resultant solutions 
were filtered, properly diluted and estimated spectro 
photometrically by keeping pH6.8buffer as blank .% drug 
remained under composed was checked for both core and 
coated tablets. 
RESULTS & DISCUSSION:  
Pre compression parameters of core tablet of 
zafirlukast: Pre-compression parameters were conducted 
for all formulations blend and were found to be satisfactory. 
Bulk density was found in the range 0.340 - 0.384 g/sqcm 
and tapped density in the range of 0.394 - 0.434 g/sqcm. 
Using these two density factors Hausner’s ratio and 
compressibility index was calculated. The powder blend of 
all formulations had Hausner’s ratio was between 1.11 – 1.17 
which indicates better flow property and compressibility 
index between 10.74 to 14.88 which indicates fair flow 
ability property. The fair flow ability property of the powder 
blend was also evidenced with angle of repose between 
25.24 – 27.97, which is below 40  indicating the good flow 
ability. 
Pre compression parameters of core tablets: 
1. Weight Variation Test: The percentage weight 
variations for all formulations were given. All the 
formulated (F1 to F9) tablets passed weight variation 
test as the % weight variation was within the 
pharmacopoeia limits. The weights of all the tablets 
were found to be uniform with low standard deviation 
values. 
2. Hardness test: The  measured  hardness  of  tablets  of  
all  the  formulations  ranged  between 3-4 kg/cm2.  
This ensures good handling characteristics of all 
batches. 
3. Disintegration test for core tablets: It was found 
between 30 – 86 seconds ensuring that all the cores of 
different formulations were rapid disintegrating type. 
4. Friability Test: The % friability was less than 0.77 % 
in all the formulations ensuring that the tablets were 
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mechanically stable. 
Evaluation of Physical parameters of compressed 
tablets of Zafirlukast 
1. Weight Variation Test: The percentage weight 
variations for all formulations were given. All the 
formulated (Z1F9 to Z6F9) tablets passed weight 
variation test as the % weight variation was within the 
pharmacopoeia limits. The weights of all the tablets 
were found to be uniform with low standard deviation 
values. 
2. Hardness test: The  measured  hardness  of  tablets  of  
all  the  formulations  ranged  between 5.12 – 5.30 
kg/cm2.  This ensures good handling characteristics of 
all batches. 
3. Thickness: The  measured  thickness  of  tablets  of  all  
the  formulations  ranged  between 4.65 - 4.85mm.  
This ensures good handling characteristics of all 
batches. 
4. Friability Test: The % friability was less than 1 % in all 
the formulations ensuring that the tablets were 
mechanically stable. 
5. Content uniformity: The  percentage  of  drug  content  
for  F1  to  F9  was  found  to be between 90.23% - 
98.86%  it complies with official specifications. The 
percentage of drug content for Z1F9 to Z6F9 was found 
to be between 93.30% - 99.71%. It complies with 
official specifications. 
6. Stability studies: Stability Studies were carried out at 
40
o
C tempand75%RH for 30days. The core tablet and 
coated tablet of selected formulation were packed in 
amber-colored bottles tightly plugged with cotton and 
capped. And % drug content was checked at regular 
time intervals. 
 
 
Fig .1 Releasemechanisam of pulsatile drug delivery system 
Table 1: Formulation table of core tablets: 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
Zafirlukast 10 10 10 10 10 10 10 10 10 
Ac-Di-Sol 5 7.5 12.5 -- -- -- -- -- -- 
Primojel -- -- -- 5 7.5 12.5 -- -- -- 
Polyplasdone XL 10 -- -- -- -- -- -- 5 7.5 12.5 
Micro crystalline cellulose Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
Magnesium.stearate 4 4 4 4 4 4 4 4 4 
Talc 2 2 2 2 2 2 2 2 2 
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Table 2: Composition of compressed coated tablets: 
 
Formulation 
 
Z1F9 
 
Z2F9 
 
Z3F9 
 
Z4F9 
 
Z5F9 
 
Z6F9 
 
Core 
 
100 
 
100 
 
100 
 
100 
 
100 
 
100 
 
Carbopol 
 
400 
  
200 
 
150 
 
250 
 
275 
 
Karaya gum 
  
400 
 
200 
 
250 
 
150 
 
125 
 
Total weight 
 
500 
 
500 
 
500 
 
500 
 
500 
 
500 
 
Table: 3 In - Vitiro release profile of  Formulation (F1-F9): 
TIME F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
5 16.78 19.96 24.47 22.59 28.88 34.40 40.11 43.26 47.13 
10 25.57 27.78 33.56 30.48 36.60 42.26 52.74 59.69 62.22 
15 34.49 39.90 42.02 41.79 49.98 53.36 63.60 66.78 70.65 
20 52.11 57.15 61.19 50.80 65.54 72.20 75.09 79.04 84.14 
25 69.90 73.30 76.62 61.60 79.59 84.47 82.97 87.23 91.10 
30 76.65 82.20 85.59 72.79 88.80 96.66 87.58 92.41 99.45 
45 87.19 91.16 97.40 84.63 97.19  93.30 98.91  
60 95.50 98.07  92.77   99.78   
 
Table 4: Cumulative %drug release of coated different formulation (Z1F9 to Z6F9): 
Time(HRS) Z1F9 Z2F9 Z3F9 Z4F9 Z5F9 Z6F9 
0 0 0 0 0 0 0 
1 0.54 0.75 0.41 0.55 0.89 0.22 
2 0.63 0.98 0.77 1.23 1.36 0.64 
3 2.03 39.78 3.69 5.60 4.47 0.84 
4 4.12 79.96 8.79 10.23 9.98 1.97 
5 19.65 95.64 26.65 21.36 26.6 13.36 
6 32.30 -- 48.87 34.45 47.48 74.46 
7 44.47 -- 66.30 66.54 69.14 85.97 
8 74.12 -- 97.90 80.21 87.19 98.89 
9 84.20 -- -- 96.54 100.01 -- 
10 95.46 -- -- -- -- -- 
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Table 5: in-vitro drug release mechanism of best core 
formulation: 
Batch Zero order First  order 
Code r2 r2 
F9 0.872 0.982 
 
 
Fig-2 Cumulative percentage of formulation F1-F3       
     
              
    Fig-3 Calibration curve of formulation F1-F3    
                                     
Drug release of core formulation F1-F3 
 
Fig-4 Cumulative percentage drug Release of core 
formulation F4-F6 
 
Fig-5 Cumulative Percentage drug release of core 
formulation F7-F9 
      
Drug release kinetics mechanisms of best formulation 
(F9): 
 
Fig-6: Zero order release kinetics for F9 
 
Fig-7: First order release kinetics for F9 
 
Table 6: Showing % Drug Content during storage 
Time in 
Days 
%Drug Content in 
Core Tablets 
%Drug Content in 
Coated Tablets 
0 98.86 99.71 
10 98.79 99.75 
20 98.81 99.70 
30 99.84 99.69 
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CONCLUSION:  
A satisfactory attempt was made towards the development 
of efficacious drug delivery systems with already existing 
active ingredient (Zafirlukast). The coating given by the 
combination of carbopol and Karayagum enhanced the drug 
release from the coated tablet and side effects were 
minimized.  On the basis of drug content, in-vitro release 
studies and its kinetic data F9 of core tablet and Z5F9 of 
were selected as optimized formulations for designing 
pulsatile device.  Finally from the above results we can 
conclude that pulsatile drug delivery system of Zafirlukast can 
be formulated using above mentioned polymers. 
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